Clinic observation on shenqi 11 flavor capsule as adjuvant treatment in advanced NSCLC patients during chemotherapy
10.3760/cma.j.issn.1673-4246.2011.12.002
- VernacularTitle:参芪十一味胶囊对晚期非小细胞肺癌的辅助治疗作用
- Author:
Wanning TONG
;
Anshan ZHUO
;
Yushu CAO
;
Shilin XU
- Publication Type:Journal Article
- Keywords:
Shenqi 11 flavor capsule;
Adjuvant treatment;
Advanced non-small cell lung cancer (NSCLC);
Chemotherapy
- From:
International Journal of Traditional Chinese Medicine
2011;33(12):1060-1063
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effects and immune function of shenqi 11 flavor capsule as an adjuvant treatment in advanced NSCLC patients during chemotherapy.Methods 58 cases of advanced NSCLC were divided into two groups by mean of digital random table method,with 29 patients in each group.GP scheme chemotherapy was applied to patients in group B,using gemcitabine (1000 mg/m2) on the 1st and 8th day intravenously (procedure should be finished within 30 minutes) and cisplatin (75 mg/m2) on the 1st day intravenously.Each cycle was 3 weeks,two cycles in total.Same scheme was applied to patients in group A and with an addition of shenqi 11 flavor capsule(1.65 g/time,3 times/d) throughout the whole procedure of chemothrapy.Recent curative effect,life quality,toxic reactions and changes in immune indexes of both groups were observed.Results Short-term response rate in group A was 48.27％ and 41.38％ in the group B (x2=0.279,P＞0.05),which showed no significant differences between the two groups.Toxic reactions such as leukopenia,hematochrome decrease and gastrointestinal reactions in the group B were significantly severe compared to group A after chemotherapy(x2 were 4.678,4.549 and 4.687 respectively,P＜0.05).As for immune indexes after chemotherapy,CD3+ (55.21 ± 3.28) ％,CD4+ (38.84±5.13) ％,CD8+ (29.86±4.83) ％,CD4+/CD8+( 1.29± 0.17) and NK cells (20.12± 2.11 ) ％in the group B indicated significant differences compared to those in group A[(62.96±4.12)％、(45.21±3.43)％、(25.23±2.79)％、(1.82±0.21)、(25.78±3.36)％],(P＜0.05).The life quality was 58.62％ in group A and 31.03％ in the group B,which showed significant difference (x2=4.462,P＜0.05).Conclusion Shenqi 11 flavor capsule as an adjuvant treatment in advanced NSCLC patients during chemotherapy can not only improve life quality of patients,alleviate the symptoms,but also enhance their immune function.
